drugset / Trial / NCT02532283

A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

NCT02532283

Phase 2 Completed 102 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the Pharmacokinetic parameters of JNJ-63623872 in combination with oseltamivir in elderly participants (aged 65 to \<= 85 years) compared to adults (aged 18 to \<= 64 years) with influenza A infection.

Timeline

Start
2015-12-11
Primary completion
2017-02-24
Completion
2017-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Pimodivir Small molecule 600 mg Oral
Background Oseltamivir Small molecule 75 mg Oral

Indications